secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2026-05-15T12:20:20+00:00
Accession:  0001493152-26-023367
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026
--------------------------------------------------------------------------------

- Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.
- Cash and equivalents $3.3M at March 31, 2026; going concern assumed through anticipated merger close.
- Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026; common stock holders get ~6% of combined co.
- Private placement of Series B convertible preferred stock from Eos affiliate raised $1.0M gross in March.
- R&D expense <$0.1M; G&A down to $1.3M from $1.8M; clinical programs on hold pending out-license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226023367/0001493152-26-023367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226023367/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer